ASAHI KASEI PHARMA CORPORATION
🇯🇵Japan
Clinical Trials
48
Active:11
Completed:27
Trial Phases
5 Phases
Phase 1:3
Phase 2:10
Phase 3:12
+2 more phases
Drug Approvals
15
NMPA:15
Drug Approvals
Fasudil Hydrochloride Injection
- Product Name
- 依立卢
- Approval Number
- 国药准字HJ20150252
- Approval Date
- Mar 19, 2025
NMPA
Isepamicin Sulfate Injection
- Product Name
- 依克沙
- Approval Number
- 国药准字HJ20171234
- Approval Date
- Aug 31, 2022
NMPA
Isepamicin Sulfate Injection
- Product Name
- 依克沙
- Approval Number
- 国药准字HJ20171235
- Approval Date
- Aug 31, 2022
NMPA
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
Phase 3
12 (40.0%)Phase 2
10 (33.3%)Phase 1
3 (10.0%)Phase 4
3 (10.0%)Not Applicable
2 (6.7%)Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes
Not Applicable
Active, not recruiting
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 200
- Registration Number
- NCT05227677
- Locations
- 🇨🇳
The third people's hospital of DATONG, Datong, Shanxi, China
🇨🇳Beijing Haidian Hospital, Beijing, China
🇨🇳Beijing Pinggu District Hospital, Beijing, China
First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS)
Phase 1
Terminated
- Conditions
- Spinal StenosisDegenerative Spondylolisthesis
- Interventions
- Other: Control
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT04483297
- Locations
- 🇨🇦
Royal Alexandra Hospital, Edmonton, Alberta, Canada
🇨🇦Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦London Health Sciences Centre, London, Ontario, Canada
Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 103
- Registration Number
- NCT03471988
- Locations
- 🇯🇵
Research site, Nagasaki, Japan
Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer
Phase 2
Completed
- Conditions
- Postoperative Stage II/III Colon Cancer
- Interventions
- Drug: ART-123 (3-day ART)Drug: ART-123 (1-day ART)Drug: Placebo
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 79
- Registration Number
- NCT02792842
Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Asahi Kasei Pharma Corporation
- Target Recruit Count
- 74
- Registration Number
- NCT02739165
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found